As antibiotic resistance continues to increase for uncomplicated UTIs, there is an urgent need for alternative treatment options. Gepotidacin (BLUJEPA), a first-in-class new antibiotic with a novel mechanism of action. It may represent a therapeutic alternative for uncomplicated UTI management. Let us explore this further.
Ozempic, Wegovy has surged in popularity in recent years. Reports indicate that people are turning to these medications as a “fast fix” for losing a few kilograms; however, the possible side effects can be dangerous, making it essential for their use to be supervised by a healthcare professional. Therefore, it is crucial to explore several pertinent questions.
Suzetrigine is the first novel painkiller the FDA has approved in more than two decades. This blog gives an overview of this medication.
Obesity is one of the most overlooked health issues. India, a developing nation, is experiencing a transitory condition of undernutrition as a result of poverty and obesity brought on by fast urbanization and industrialization. The previous standards for Asian Indian obesity published 15 years back were based exclusively on BMI measurements. A thorough revision was required in light of the limits of BMI incorrectly diagnosing obesity and the recent findings linking Asian Indian’s generalized and abdominal adiposity to early-onset co-morbid conditions. To improve the accuracy of detecting obesity and the dangers that it poses to Asian Indians residing in India, a new definition of obesity was created.
Nafithromycin is India’s first indigenous antibiotic and the first significant innovation in its antibiotic class in over 30 years. It represents a breakthrough in the fight against antibiotic resistance. We address a few questions regarding this milestone antibiotic, Nafithromycin, here.
Obesity and diabetes are becoming increasingly prevalent worldwide. India has the second-highest number of people with diabetes and the third-highest percentage of obese people. As a result, advanced and novel therapeutic options are required. Tirzepatide is a new drug approved in many countries globally as a once-weekly subcutaneous injectable for type 2 diabetes and obesity. India’s drug regulator, CDSCO, recently approved its marketing nationwide. Herein, we present a brief overview of the key characteristics of Tirzepatide, its advantages, and shortcomings.
